


**What is claimed is:**

1. A compound of Formula (I):



or pharmaceutically acceptable salt thereof, wherein:

$R^1$  is H or  $C_1$ - $C_8$  alkyl;

$R^2$  is  $C_1$ - $C_8$  alkyl;

$R^3$  is H, aryl, arylalkyl-O-, arylalkyl-N( $R^5$ )-, aryl-N( $R^5$ )-, or heteroaryl, wherein said aryl is optionally substituted with up to two substituents selected from  $C_1$ - $C_8$  alkyl, halogen, perhaloalkyl, and alkoxy;

$R^4$  is H, arylalkyl-O-, alkoxy, or aryloxy; and

$R^5$  is H,  $C_1$ - $C_8$  alkyl, aryl,  $C_1$ - $C_8$  alkenyl, heteroaryl, arylalkyl, heteroarylalkyl, perhaloalkyl, or allyl;

with the provisos:

- a) at least one of  $R^3$  and  $R^4$  is other than H;
- b) when  $R^3$  is arylalkyl-N( $R^5$ )- or aryl-N( $R^5$ )- and  $R^4$  is H, then  $R^1$  is H;
- c) when  $R^1$  is H,  $R^2$  is  $CH_3$  and  $R^3$  is 2-chlorophenyl, then  $R^4$  is other than H; and
- d) when  $R^1$  is H,  $R^2$  is  $CH_3$  and  $R^3$  is 2-thienyl, then  $R^4$  is other than methoxy.

2. The compound of claim 1 wherein:

$R^1$  is H or  $C_1$ - $C_8$  alkyl;


$R^2$  is  $C_1$ - $C_8$  alkyl;

$R^3$  is H, aryl, arylalkyl-O-, arylalkyl-N( $R^5$ )-, or aryl-N( $R^5$ )- wherein said aryl is optionally substituted with up to two substituents selected from  $C_1$ - $C_8$  alkyl, halogen, perhaloalkyl, and alkoxy;

$R^4$  is H or aryloxy; and


$R^5$  is H,  $C_1$ - $C_8$  alkyl, aryl,  $C_1$ - $C_8$  alkenyl, heteroaryl, arylalkyl, heteroarylalkyl, perhaloalkyl, or allyl.

3. A compound of claim 1 or 2 having Formula (Ia):



or pharmaceutically acceptable salt form thereof.

4. A compound of claim 1 or 2 having Formula (Ib):



(Ib)

- 5 or pharmaceutically acceptable salt form thereof.

5. The compound of any one of claims 1 to 4 wherein:

R<sup>1</sup> is H or C<sub>1</sub>-C<sub>8</sub> alkyl;

R<sup>2</sup> is C<sub>1</sub>-C<sub>8</sub> alkyl;

10 R<sup>3</sup> is arylalkyl-O-, arylalkyl-N(R<sup>5</sup>)-, or aryl-N(R<sup>5</sup>)-;

R<sup>4</sup> is H; and

R<sup>5</sup> is H, C<sub>1</sub>-C<sub>8</sub> alkyl, aryl, C<sub>1-8</sub> alkenyl, heteroaryl, arylalkyl, heteroarylalkyl, perhaloalkyl, or allyl.

- 15 6. The compound of any one of claims 1 to 4 wherein:

R<sup>1</sup> is H or C<sub>1</sub>-C<sub>8</sub> alkyl;

R<sup>2</sup> is C<sub>1</sub>-C<sub>8</sub> alkyl;

R<sup>3</sup> is arylalkyl-O-, arylalkyl-N(R<sup>5</sup>)-, or aryl-N(R<sup>5</sup>)-;

R<sup>4</sup> is H; and

20 R<sup>5</sup> is H, C<sub>1</sub>-C<sub>8</sub> alkyl, or aryl.

7. The compound of any one of claims 1 to 4 wherein:

R<sup>1</sup> is H or C<sub>1</sub>-C<sub>8</sub> alkyl;

R<sup>2</sup> is C<sub>1</sub>-C<sub>8</sub> alkyl;

25 R<sup>3</sup> is arylalkyl-O-; and

R<sup>4</sup> is H.

8. The compound of any one of claims 1 to 4 wherein:

R<sup>1</sup> is H or C<sub>1</sub>-C<sub>8</sub> alkyl;

30 R<sup>2</sup> is C<sub>1</sub>-C<sub>8</sub> alkyl;

R<sup>3</sup> is H; and

R<sup>4</sup> is arylalkyl-O-.

9. The compound of any one of claims 1 to 4 wherein:

R<sup>1</sup> is H;  
R<sup>2</sup> is C<sub>1</sub>-C<sub>4</sub> alkyl;  
R<sup>3</sup> is arylalkyl-O-; and  
R<sup>4</sup> is H.

5

10. The compound of any one of claims 1 to 4 wherein:

R<sup>1</sup> is H;  
R<sup>2</sup> is C<sub>1</sub>-C<sub>8</sub> alkyl;  
R<sup>3</sup> is arylalkyl-N(R<sup>5</sup>)-;  
R<sup>4</sup> is H; and  
R<sup>5</sup> is H, C<sub>1</sub>-C<sub>8</sub> alkyl, or aryl.

10

11. The compound of any one of claims 1 to 4 wherein:

R<sup>1</sup> is H;  
R<sup>2</sup> is methyl;  
R<sup>3</sup> is phenyl, phenylalkyl-O-, phenylalkyl-N(R<sup>5</sup>)-, or phenyl-N(R<sup>5</sup>)-;  
R<sup>4</sup> is H; and  
R<sup>5</sup> is H.

15

- 20 12. The compound of any one of claims 1 to 4 wherein:

R<sup>1</sup> is H;  
R<sup>2</sup> is methyl;  
R<sup>3</sup> is H; and  
R<sup>4</sup> is phenylalkyl-O-.

25

13. The compound of any one of claims 1 to 4 wherein:

R<sup>1</sup> is H;  
R<sup>2</sup> is methyl;  
R<sup>3</sup> is phenyl optionally substituted with up to two halogens, or R<sup>3</sup> is pyridinyl; and  
R<sup>4</sup> is H or alkoxy.

30

14. The compound of any one of claims 1 to 4 wherein:

R<sup>1</sup> is H;  
R<sup>2</sup> is methyl;  
R<sup>3</sup> is phenyl optionally substituted with up to two fluoro; and  
R<sup>4</sup> is H or methoxy.

35

15. The compound of any one of claims 1 to 4 wherein:

R<sup>1</sup> is H;

R<sup>2</sup> is methyl;

R<sup>3</sup> is pyridinyl; and

R<sup>4</sup> is H.

16. A compound of any one of claims 1 to 4 selected from:

- a) 7-benzyloxy-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
  - b) 1-methyl-7-(1-phenyl-ethoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
  - c) 1-methyl-7-phenethyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
  - d) 1-methyl-7-(3-phenyl-propoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
  - e) benzyl-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;
  - f) (5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-(1'-phenyl-ethyl)-amine;
  - g) benzyl-methyl-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;
  - h) (5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-phenethyl-amine;
  - i) (5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-(3-phenyl-propyl)-amine;
  - j) (5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-phenyl-amine; and
  - k) 1-methyl-8-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- or pharmaceutically acceptable salt thereof.

17. A compound of any one of claims 1 to 4 selected from:

- a) 8-Benzyloxy-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
  - b) 7-Benzyloxy-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
  - c) 1-Methyl-8-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
  - d) 7-Methoxy-1-methyl-8-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
  - e) 8-(2-Fluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
  - f) 8-(3-Fluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
  - g) 8-(4-Fluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
  - h) 8-(2,6-Difluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
  - i) 8-(2,3-Difluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
  - j) 8-(2,5-Difluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
  - k) 1-Methyl-8-pyridin-3-yl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; and
  - l) 1-Methyl-8-pyridin-2-yl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- or pharmaceutically acceptable salt thereof.

18. A composition comprising a compound of any one of claims 1 to 17 and a pharmaceutically acceptable carrier.

19. A method of treating disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, sleep apnea or HDL-related condition comprising administering to a patient in need of said treating a therapeutically effective amount of a compound of any one of claims 1 to 17.
20. The method of claim 19 wherein the disorders of the central nervous system are selected from depression, atypical depression, bipolar disorders, anxiety disorders, obsessive-compulsive disorders, social phobias or panic states, sleep disorders, sexual dysfunction, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality disorders, age-related behavioral disorders, behavioral disorders associated with dementia, organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome, drug and alcohol addiction, obesity, bulimia, anorexia nervosa and premenstrual tension.
21. The method according to claim 19 wherein the disorder of the central nervous system is obesity.
22. The method according to claim 19 wherein the sexual dysfunction is male erectile dysfunction.
23. A method of decreasing food intake of a mammal comprising administering to said mammal a therapeutically effective amount of a compound of any one of claims 1 to 17.
24. A method of inducing satiety in a mammal comprising administering to said mammal a therapeutically effective amount of a compound of any one of claims 1 to 17.
25. A method of controlling weight gain of a mammal comprising administering to said mammal a therapeutically effective amount of a compound of any one of claims 1 to 17.
26. A method of treating obesity comprising administering to a patient in need of such treating a therapeutically effective amount of a compound of any one of claims 1 to 17.
27. A compound according to any one of claims 1 to 17 for use in a method of treatment of a patient by therapy.

28. A compound according to any one of claims 1 to 17 for use in a method of treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus; sleep apnea or HDL-related condition.
- 5 29. A compound according to any one of claims 1 to 17 for use in a method of treatment of disorders of the central nervous system selected from depression, atypical depression, bipolar disorders, anxiety disorders, obsessive-compulsive disorders, social phobias or panic states, sleep disorders, sexual dysfunction, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality disorders, age-related behavioral disorders, behavioral disorders associated with dementia, 10 organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome, drug and alcohol addiction, obesity, bulimia, anorexia nervosa and premenstrual tension.
30. A compound according to any one of claims 1 to 17 for use in a method for the treatment of 15 obesity.
31. A compound according to any one of claims 1 to 17 for use in a method for the treatment of male erectile dysfunction.
- 20 32. A compound according to any one of claims 1 to 17 for use in a method of decreasing food intake of a mammal.
33. A compound according to any one of claims 1 to 17 for use in a method of inducing satiety in a mammal. 25
34. A compound according to any one of claims 1 to 17 for use in a method controlling weight gain of a mammal.
35. Use of a compound according to any one of claims 1 to 17 for the manufacture of a 30 medicament for use in a method of treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus; sleep apnea or HDL-related condition.
- 35 36. Use of a compound according to any one of claims 1 to 17 for the manufacture of a medicament for use in a method of treatment of disorders of the central nervous system selected from depression, atypical depression, bipolar disorders, anxiety disorders, obsessive-compulsive disorders, social phobias or panic states, sleep disorders, sexual dysfunction,

psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality disorders, age-related behavioral disorders, behavioral disorders associated with dementia, organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome, drug and alcohol addiction, obesity, bulimia, anorexia nervosa and premenstrual tension.

37. Use of a compound according to any one of claims 1 to 17 for the manufacture of a medicament for the treatment of obesity.

38. Use of a compound according to any one of claims 1 to 17 for the manufacture of a medicament for the treatment of male erectile dysfunction.

39. Use of a compound according to any one of claims 1 to 17 for the manufacture of a medicament for use in a method of decreasing food intake of a mammal.

40. Use of a compound according to any one of claims 1 to 17 for the manufacture of a medicament for use in a method of inducing satiety in a mammal.

41. Use of a compound according to any one of claims 1 to 17 for the manufacture of a medicament for use in a method controlling weight gain of a mammal.